Leading European life‑science investors including Forbion, Novo Holdings and Sofinnova launched the European Life Science Coalition to mobilize private and public capital for the region’s biotech sector. The group argues Europe’s fragmented capital markets and limited later‑stage funding push many companies to list in the U.S., and it seeks policy and funding changes to retain scale‑ups locally. The coalition plans to lobby for regulatory, tax and public‑funding reforms and to coordinate larger pooled investment vehicles. Founders and policymakers will monitor whether the initiative translates into quicker late‑stage financings and more Europe‑based IPOs or M&A activity.